Abstract
Background: Risk-reducing salpingo-oophorectomy (RRSO) is recommended for women at increased risk of breast and ovarian cancer. We launched a prospective study of women receiving RRSO, including those with mutations in genes beyond BRCA1/2.
Patients and methods: 80 women were enrolled for RRSO with sectioning and extensively examining the fimbriae (SEE-FIM) protocol between October 2016 and June 2022. The majority of participants had inherited susceptibility gene mutations or a family history suggesting ovarian cancer risk, while patients with isolated metastatic high-grade serous cancer of unknown origin were also included.
Results: Overall, two patients had isolated metastatic high-grade serous cancer with unknown origin, and four patients had family histories but refused to take genetic tests. The rest 74 patients harbored deleterious susceptible gene, including 43 (58.1%) with BRCA1 mutation, and 26 (35.1%) with BRCA2 mutation, respectively. Other mutated genes included ATM (1), BRIP1(1), PALB2(1), MLH1(1) and TP53 (1) in each patient. Among the 74 mutation carriers, three (4.1%) cancers were recognized, one (1.4%) was found to have serous tubal intraepithelial carcinoma (STIC), and five patients (6.8%) was diagnosed with serous tubal intraepithelial lesions (STILs). P53 signature was recognized in 24 patients (32.4%). For other genes, MLH1 mutation carrier had endometrial atypical hyperplasia and p53 signature in fallopian tubes. The germline TP53 mutation carrier had STIC in the surgical specimens. Evidence for precursor escape was also recognized in our cohort.
Conclusion: Our study demonstrated clinic-pathological findings of patients at increased risk of breast and ovarian cancer, and expand the clinical application of SEE-FIM protocol.
Introduction
Ovarian cancer is often termed a "silent killer" due to its asymptomatic progression and late-stage diagnosis. For women with inherited genetic predispositions, such as BRCA1 or BRCA2 mutations, Risk-Reducing Salpingo-Oophorectomy (RRSO) is the standard preventive measure. While Western data on RRSO is extensive, there is a significant gap in research concerning Chinese populations and the risks associated with moderate-penetrance genes like ATM, PALB2, or BRIP1. This study evaluates the pathological outcomes of RRSO in a high-risk Chinese cohort using the rigorous SEE-FIM protocol.
Methods and Datasets
The study followed 80 women at the Fudan University Shanghai Cancer Center from 2016 to 2022. Researchers employed the SEE-FIM (Sectioning and Extensively Examining the Fimbriae) protocol, which involves sectioning the entire ovary and fallopian tube at 2–3 mm intervals and performing extensive longitudinal sectioning of the fimbriated end. Immunohistochemistry (IHC) for p53 and Ki-67 was used to identify p53 signatures and Serous Tubal Intraepithelial Carcinoma (STIC).
The cohort consisted of 74 mutation carriers (including BRCA1, BRCA2, and rarer mutations like TP53 and MLH1), 4 patients with strong family histories who declined genetic testing, and 2 patients with metastatic high-grade serous cancer (HGSC) of unknown origin.
Key Results
Pathological Findings
Among the 74 mutation carriers, occult (hidden) malignancies were detected in 4.1% of cases. Furthermore, 1.4% exhibited STIC, 6.8% had Serous Tubal Intraepithelial Lesions (STILs), and 32.4% showed p53 signatures—the earliest detectable step toward malignancy. Notably, significant lesions were found in non-BRCA carriers, such as STIC in a TP53 mutation carrier and STIL in a BRIP1 carrier.
Surgical Timing and Personal History
Analysis of the cohort revealed that patients with a personal history of breast cancer typically underwent RRSO at a younger age than those without. This trend is likely due to increased medical surveillance following a breast cancer diagnosis and the potential for oophorectomy to serve as a component of hormonal therapy.
Discussion
The findings strongly support the theory that many ovarian cancers originate in the fallopian tubes. The observation of "precursor escape"—where precursor lesions exist in the tube alongside ovarian tumors without invasive tubal cancer—suggests that malignant cells may seed the ovary before a primary tubal tumor fully develops.
While the study is limited by a small sample size for rare mutations and its single-center nature, it underscores the importance of applying the SEE-FIM protocol to a broader spectrum of genetic risks beyond BRCA1/2 to improve early detection and prevention strategies.
Summary updated